NYSEAMERICAN:AMPE - Ampio Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.32 +0.01 (+0.43 %)
(As of 07/16/2018 04:00 PM ET)
Previous Close$2.39
Today's Range$2.29 - $2.40
52-Week Range$0.38 - $4.95
Volume23,404 shs
Average Volume1.01 million shs
Market Capitalization$197.70 million
P/E RatioN/A
Dividend YieldN/A
Beta0.51
Ampio Pharmaceuticals logoAmpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process; and decreasing vascular permeability. Its product pipeline includes Ampion, an intra-articular injection for the treatment of osteoarthritis of the knee; and Optina, an oral agent for the treatment of diabetic macular edema. Ampio Pharmaceuticals, Inc. is headquartered in Englewood, Colorado.

Receive AMPE News and Ratings via Email

Sign-up to receive the latest news and ratings for AMPE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSEAMERICAN:AMPE
CUSIP03209T10
Phone+1-720-4376500

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-965.03%
Return on Assets-151.95%

Miscellaneous

EmployeesN/A
Outstanding Shares86,320,000
Market Cap$197.70

The Truth About Cryptocurrencies

Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Frequently Asked Questions

What is Ampio Pharmaceuticals' stock symbol?

Ampio Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AMPE."

How were Ampio Pharmaceuticals' earnings last quarter?

Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) posted its quarterly earnings data on Tuesday, February, 24th. The specialty pharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.20) by $0.01. The specialty pharmaceutical company earned $0.02 million during the quarter. View Ampio Pharmaceuticals' Earnings History.

What is the consensus analysts' recommendation for Ampio Pharmaceuticals?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ampio Pharmaceuticals in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Are investors shorting Ampio Pharmaceuticals?

Ampio Pharmaceuticals saw a increase in short interest during the month of June. As of June 29th, there was short interest totalling 14,752,101 shares, an increase of 39.8% from the June 15th total of 10,555,723 shares. Based on an average daily trading volume, of 1,744,324 shares, the short-interest ratio is currently 8.5 days. Approximately 19.0% of the company's shares are short sold. View Ampio Pharmaceuticals' Current Options Chain.

Who are some of Ampio Pharmaceuticals' key competitors?

Who are Ampio Pharmaceuticals' key executives?

Ampio Pharmaceuticals' management team includes the folowing people:
  • Mr. Michael E. Macaluso, Founder, Chairman & CEO (Age 66)
  • Mr. Thomas E. Chilcott III, CFO, Treasurer & Sec. (Age 50)
  • Ms. Holli Cherevka, Chief Operating Officer (Age 35)
  • Dr. David Bar-Or, Chief Scientific Officer & Director (Age 69)

Has Ampio Pharmaceuticals been receiving favorable news coverage?

News headlines about AMPE stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ampio Pharmaceuticals earned a daily sentiment score of 0.05 on Accern's scale. They also assigned news headlines about the specialty pharmaceutical company an impact score of 45.47 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Ampio Pharmaceuticals?

Shares of AMPE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ampio Pharmaceuticals' stock price today?

One share of AMPE stock can currently be purchased for approximately $2.32.

How big of a company is Ampio Pharmaceuticals?

Ampio Pharmaceuticals has a market capitalization of $197.70 million.

How can I contact Ampio Pharmaceuticals?

Ampio Pharmaceuticals' mailing address is 373 Inverness Pkwy Ste 200, ENGLEWOOD, CO 80112-5898, United States. The specialty pharmaceutical company can be reached via phone at +1-720-4376500.


MarketBeat Community Rating for Ampio Pharmaceuticals (NYSEAMERICAN AMPE)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  91 (Vote Outperform)
Underperform Votes:  84 (Vote Underperform)
Total Votes:  175
MarketBeat's community ratings are surveys of what our community members think about Ampio Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMPE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMPE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.